What is the price target for ATHA stock?
7 analysts have analysed ATHA and the average price target is 4.08 USD. This implies a price decrease of -39.56% is expected in the next year compared to the current price of 6.75.
ATHIRA PHARMA INC (ATHA) Forecast, Price Target & Analyst Ratings
NASDAQ:ATHA • US04746L2034
Current stock price
6.75 USD
-0.44 (-6.12%)
At close:
6.9496 USD
+0.2 (+2.96%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ATHIRA PHARMA INC (ATHA).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Feb 25, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.87
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$4.08
Upside
-39.56%
From current price of $6.75 to mean target of $4.08, Based on 7 analyst forecasts
Low
$4.04
Median
$4.08
High
$4.20
Price Target Revisions
1 Month
0.00%
3 Months
700.00%
Price Target Summary
7 Wall Street analysts provided a forecast for the next 12 months for ATHA. The average price target is 4.08 USD. This implies a price decrease of -39.56% is expected in the next year compared to the current price of 6.75.
The average price target has been revised upward by 700% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
45.71%
ATHA was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about ATHA.
In the previous month the buy percentage consensus was at a similar level.
ATHA was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-09-19 | Mizuho | Downgrade | Outperform -> Neutral |
| 2024-09-04 | BTIG | Downgrade | Buy -> Neutral |
| 2024-09-04 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2024-08-19 | Rodman & Renshaw | Initiate | Buy |
| 2024-06-20 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-05-16 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-08-11 | JMP Securities | Maintains | Outperform -> Outperform |
| 2023-05-15 | Mizuho | Maintains | Buy -> Buy |
| 2023-03-30 | BTIG | Maintains | Buy |
| 2023-03-24 | JMP Securities | Reiterate | Market Outperform |
| 2022-07-07 | Mizuho | Initiate | Buy |
| 2022-06-23 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2022-06-23 | Stifel | Downgrade | Buy -> Hold |
| 2022-06-23 | Jefferies | Downgrade | Buy -> Hold |
| 2022-05-10 | BTIG | Initiate | Buy |
| 2022-04-21 | Berenberg | Initiate | Buy |
| 2021-12-15 | Goldman Sachs | Initiate | Neutral |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Feb 25, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.87
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 77.64%
- Number of Analysts
- 4
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
15.76%
EPS (3 Months)
15.76%
Next Earnings Summary
ATHA is expected to report earnings on 2/25/2026. The consensus EPS estimate for the next earnings is -0.87 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2025 - 2031
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||||||||
| EBITDA YoY % growth | N/A | N/A | N/A | -63.54M -98.44% | -93.17M -46.63% | -126.125M -35.37% | -95.805M 24.04% | N/A 26.17% | N/A -4.84% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -5.01M | -5.45M -8.78% | -20M -266.97% | -64.02M -220.10% | -94.02M -46.86% | -127.094M -35.18% | -96.775M 23.86% | N/A 71.96% | N/A 183.46% | N/A 0.90% | N/A -386.16% | N/A -30.42% | N/A -26.91% | N/A 44.39% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -15.00 11.76% | -22.70 -51.33% | -30.90 -36.12% | -25.30 18.12% | N/A 73.83% | N/A 25.42% | N/A 95.87% | N/A | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.87 77.64% | -0.19 91.57% | -0.06 96.60% | -0.05 96.96% | -0.05 94.15% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -2.958M 81.00% | -7.854M 17.64% | -7.854M -7.72% | -7.854M -14.26% | -7.854M -165.52% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
25.82%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
ATHIRA PHARMA INC / ATHA Forecast FAQ
When does ATHIRA PHARMA INC (ATHA) report earnings?
ATHIRA PHARMA INC (ATHA) will report earnings on 2026-02-25, after the market close.
What are the consensus estimates for ATHA stock next earnings?
The consensus EPS estimate for the next earnings of ATHIRA PHARMA INC (ATHA) is -0.87 USD and the consensus revenue estimate is 0 USD.